{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:51:49Z","timestamp":1794001909211,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020948","name":"AstraZeneca Gothenburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jchf.2023.09.007","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T09:07:05Z","timestamp":1695805625000},"page":"631-644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Contemporary Use and Implications of\u00a0Beta-Blockers in Patients With HFmrEF\u00a0or HFpEF"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-5865","authenticated-orcid":false,"given":"Alexander","family":"Peikert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A.","family":"Bart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J.","family":"Kulac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Petersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2023.09.007_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2023.09.007_bib2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cardfail.2021.04.015","article-title":"Association between \u03b2-blockers and outcomes in heart failure with preserved ejection fraction: current insights from the SwedeHF Registry","volume":"27","author":"Meyer","year":"2021","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2023.09.007_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2023.09.007_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"10.1016\/j.jchf.2023.09.007_bib5","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.09.007_bib6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCHEARTFAILURE.112.972794","article-title":"Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial","volume":"6","author":"Shah","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2023.09.007_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2023.09.007_bib8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.amjcard.2023.01.050","article-title":"Physician perspectives on the use of beta blockers in heart failure with preserved ejection fraction","volume":"193","author":"Musse","year":"2023","journal-title":"Am J Cardiol"},{"issue":"8 Pt 1","key":"10.1016\/j.jchf.2023.09.007_bib9","first-page":"893","article-title":"Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction","volume":"11","author":"Arnold","year":"2023","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.09.007_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jchf.2023.09.007_bib11","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jchf.2023.09.007_bib12","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jchf.2023.09.007_bib13","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.09.007_bib14","first-page":"184","article-title":"Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial","volume":"10","author":"Solomon","year":"2022","journal-title":"J\u00a0Am Coll Cardiol HF"},{"issue":"12","key":"10.1016\/j.jchf.2023.09.007_bib15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.09.007_bib16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J\u00a0R Stat Soc Ser B Stat Methodol"},{"key":"10.1016\/j.jchf.2023.09.007_bib17","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/ejhf.2064","article-title":"Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial","volume":"22","author":"Anker","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.09.007_bib18","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1001\/jama.2023.5942","article-title":"Global variations in heart failure etiology, management, and outcomes","volume":"329","author":"Joseph","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2023.09.007_bib19","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2023.09.007_bib20","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.09.007_bib21","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.09.007_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart\u00a0Failure Study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.09.007_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2023.09.007_bib24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jacc.2011.03.057","article-title":"Influence of global region on outcomes in heart failure \u03b2-blocker trials","volume":"58","author":"O'Connor","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.09.007_bib25","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/01.CIR.0000065187.80707.18","article-title":"Beta-blockers in chronic heart failure","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.09.007_bib26","first-page":"246","article-title":"Utilizing NT-proBNP for eligibility and enrichment in trials in HFpEF, HFmrEF, and HFrEF","volume":"6","author":"Savarese","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.09.007_bib27","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jamacardio.2018.2568","article-title":"Association of natriuretic peptides with cardiovascular prognosis in heart failure with preserved ejection fraction: secondary analysis of the TOPCAT randomized clinical trial","volume":"3","author":"Myhre","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.09.007_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/jamacardio.2022.5320","article-title":"Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: the myPACE randomized clinical trial","volume":"8","author":"Infeld","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.09.007_bib29","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/CIRCULATIONAHA.115.017119","article-title":"Effect of selective heart rate slowing in heart failure with preserved ejection fraction","volume":"132","author":"Pal","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.09.007_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31963","article-title":"Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction: a meta-analysis","volume":"5","author":"Xiang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jchf.2023.09.007_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cardfail.2019.08.020","article-title":"Beta-blocker cessation in stable outpatients with heart failure with a preserved ejection fraction","volume":"26","author":"Nambiar","year":"2020","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2023.09.007_bib32","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacc.2021.11.033","article-title":"Optimal background pharmacological therapy for heart failure patients in clinical trials: JACC review topic of the week","volume":"79","author":"Fiuzat","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.09.007_bib33","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/ejhf.2722","article-title":"Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril\/valsartan","volume":"24","author":"Yang","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.jchf.2023.09.007_bib34","first-page":"1380","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to polypharmacy status","volume":"11","author":"Peikert","year":"2023","journal-title":"J Am Coll Cardiol HF"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923006157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923006157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T21:33:17Z","timestamp":1712007197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177923006157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2213177923006157"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2023.09.007","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary Use and Implications of\u00a0Beta-Blockers in Patients With HFmrEF\u00a0or HFpEF","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2023.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}